Evaluation of Eye Health Benefits of Blueberry Chewable Tablets

NCT ID: NCT04348110

Last Updated: 2021-01-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

57 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-17

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the efficacy of blueberry chewable tablets on Eye Health

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Eye

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo tablets

Group Type PLACEBO_COMPARATOR

Placebo tablets

Intervention Type DIETARY_SUPPLEMENT

consume 2 tablets per day for 8 weeks

Blueberry Chewable Tablets

Group Type EXPERIMENTAL

Blueberry Chewable Tablets

Intervention Type DIETARY_SUPPLEMENT

consume 2 tablets per day for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo tablets

consume 2 tablets per day for 8 weeks

Intervention Type DIETARY_SUPPLEMENT

Blueberry Chewable Tablets

consume 2 tablets per day for 8 weeks

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NutraView® Tablets

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult men and women over 20 years old
* Use 3C products over 6 hours per day
* Symptoms of dry eyes or tired eyes
* Tear Break-Up Time is 10 seconds less
* No history of ocular surgery (strabismus surgery, refractive surgery etc.)

Exclusion Criteria

* Have systemic diseases affecting the front surface of the eyes.
* Long-term use of drugs or eye drops that affect the condition of the front surface of the eyes
* Long-term contact lens wear
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

TCI Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bo-Yie Chen

Role: PRINCIPAL_INVESTIGATOR

Chung Shan Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chung Shan Medical University

Taichung, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CS19152

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Acute Cognitive Effects of Brain Edge
NCT07018674 NOT_YET_RECRUITING NA